Rutgers New Jersey Medical School

What Rutgers New Jersey Medical School does

Rutgers New Jersey Medical School (NJMS) is a public medical school founded in 1954 as Seton Hall College of Medicine and Dentistry, headquartered in Newark, New Jersey, and operating as a constituent school of Rutgers, The State University of New Jersey. The institution delivers a tripartite mission of medical education, clinical patient care, and biomedical research across approximately 5,001-10,000 employees, with New Jersey's leading NIH funding position held continuously since 2015. NJMS serves prospective medical students, residents, fellows, patients throughout northern New Jersey, and an international research community, while operating within the Rutgers Biomedical and Health Sciences umbrella.

Name

Rutgers New Jersey Medical School

Legal name

Rutgers New Jersey Medical School

Website

https://njms.rutgers.edu

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Rutgers New Jersey Medical School is a public medical school in Newark, NJ, delivering MD, residency, and fellowship education; clinical care through University Hospital and a statewide hospital affiliate network; and New Jersey-leading NIH-funded biomedical research with deep specialty expertise in infectious disease and TB diagnostics.

Ownership category

akta.pro rank

Product category

Medical Education and Academic Healthcare

NAICS

Colleges, Universities, and Professional Schools (6113), General Medical and Surgical Hospitals (6221), Colleges, Universities, and Professional Schools (61131), Health Care and Social Assistance (62)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Schools of Public Health (EDAHAGAD), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

Keywords

• Medical education programs
• Graduate medical education
• Biomedical research services
• Clinical patient care
• Infectious disease research

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Medical Education: Tuition and fees from MD programs, graduate medical education (residency/fellowship), and continuing medical education.
2. Clinical Care Services: Patient care services through University Hospital and affiliated hospitals including telehealth visits, procedures, and consultations.
3. Research Grants and Funding: Federal funding from NIH, CDC, foundations (Bill & Melinda Gates Foundation, NJ Health Foundation), licensing income, and pharmaceutical/biotech industry partnerships.
4. Licensing and Royalties: Revenue from licensing diagnostic technologies and intellectual property to industry partners.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Rutgers New Jersey Medical School is a public medical school that provides MD education, graduate medical education (residency and fellowship programs), and continuing medical education across multiple specialties. It delivers comprehensive patient care services through University Hospital and a network of affiliated teaching hospitals, and conducts biomedical and translational research with strengths in infectious diseases, tuberculosis, immunity, inflammation, and cardiovascular disease through institutes including the Public Health Research Institute (PHRI), the Institute for Infectious and Inflammatory Diseases (i3D), and the Global Tuberculosis Institute.

Product overview

Rutgers New Jersey Medical School is a medical school offering a comprehensive portfolio of medical education programs, clinical patient care services, and biomedical research. The institution operates as a platform structure with core education and patient care services complemented by specialized research institutes and centers. Key products include: medical education (MD programs, residencies, fellowships), patient care including telehealth services, and research institutes including the Public Health Research Institute (PHRI), Institute for Infectious & Inflammatory Diseases (i3D), Center for Immunity & Inflammation (CII), Center for Emerging Pathogens, and Global Tuberculosis Institute. The school also contributes to TB diagnostics through its role in the FEND-TB consortium, supporting technologies like the Quantum Electrochemical Spectroscopy (QES) platform, TB-IGRA, Xpert MTB/RIF, and Fujifilm SILVAMP TB LAM. Vascular surgery training programs include fellowship and integrated residency offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Education Programs (MD, Residency, Fellowship) Doctor of Medicine (MD) degree program plus graduate medical education including residency programs, fellowship programs, and continuing medical education across multiple specialties such as vascular surgery, general surgery, and infectious diseases, for prospective and current medical students, residents, and fellows.
• Patient Care Services Comprehensive healthcare services including primary care, specialty care, surgical services, cardiovascular care, vascular surgery, trauma care at the 519-bed University Hospital (Level 1 Trauma Center), and care at affiliated RWJBarnabas Health facilities, VA New Jersey Healthcare System, and other teaching hospitals.
• Telehealth Visits Virtual healthcare appointment service enabling patients to schedule and conduct remote medical consultations with NJMS physicians and specialists.
• Vascular Surgery Fellowship Program ACGME-accredited two-year vascular surgery fellowship program offered to physicians seeking advanced subspecialty training in vascular surgery.
• Vascular Surgery Integrated Residency Program ACGME-accredited five-year integrated vascular surgery residency program for physicians entering vascular surgery training directly from medical school.
• Xpert MTB/RIF Assay (Cepheid GeneXpert) Molecular diagnostic test for active tuberculosis and rifampicin resistance, using PHRI-developed molecular beacon technology in the Cepheid GeneXpert platform; endorsed by WHO for worldwide use in 2010.
• TB-IGRA Reagents M. tuberculosis-specific reagents developed by PHRI for Interferon-gamma release assays used in diagnosing latent tuberculosis infection.
• Fujifilm SILVAMP TB LAM Assay Urine-based TB diagnostic assay detecting lipoarabinomannan (LAM) with significantly greater sensitivity than previous methods, using novel human monoclonal antibodies developed by PHRI researchers and recognized with a 2024 Edison Patent Award.

Quantifiable outcome

• New Jersey's leading NIH funding recipient since 2015
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• RWJBarnabas HealthcoreStrategic or Co-development Partner · 1 March 2026RWJBarnabas Health and Rutgers Health announced official launch of public-private partnership in 2018. Physician-scientists collaborate on cardiovascular research presenting 70 abstracts at ACC.26. Partnership provides New Jersey's largest academic healthcare system combining world-class medical education with comprehensive clinical care.
• ProbiuscoreStrategic or Co-development Partner · 1 January 2026Probius is collaborating with the FEND-TB consortium led by Rutgers-New Jersey Medical School to advance development of its Quantum Electrochemical Spectroscopy (QES) platform for tuberculosis screening in low- and middle-income countries. Clinical validation studies are planned across multiple sites in sub-Saharan Africa with regulatory pathways targeting FDA clearance and WHO prequalification.
• World Health Organization (WHO)coreOthersWHO endorsed the rapid tuberculosis test developed by Dr. David Alland for worldwide use in 2010. WHO prequalification pathway is being pursued for new TB diagnostic technologies including Fujifilm SILVAMP TB LAM.
• International Union Against Tuberculosis and Lung Disease (The Union)minorStrategic or Co-development PartnerDr. Rajita Bhavaraju selected to receive Lifetime Service Award from The Union's North America Region for work with TB-RePORT International Coordinating Center.
• Foundation for Innovative New Diagnostics (FIND)coreStrategic or Co-development PartnerFIND collaborated with Rutgers on development of Fujifilm SILVAMP TB LAM assay, providing expertise in diagnostic development and global health implementation.
• FujifilmcoreStrategic or Co-development PartnerFujifilm collaborated with Rutgers on development of SILVAMP TB LAM assay for detecting tuberculosis biomarker in urine with significantly greater sensitivity than previous methods.
• FDAcoreOthersRegulatory pathway for TB diagnostic platforms including FDA clearance being pursued for QES platform and other diagnostic technologies developed through consortium partnerships.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Others

• Cepheid (a Danaher company): Developer of the GeneXpert platform that commercialized PHRI's molecular beacon technology in the Xpert MTB/RIF assay. Functions as a commercialization partner rather than a peer, but is the most direct counterpart for translating NJMS's TB diagnostic IP into deployed global health products.

Direct peers

• Rutgers Robert Wood Johnson Medical School: The other Rutgers medical school currently being integrated with NJMS to form the unified Rutgers School of Medicine under anticipated 2027 LCME accreditation. Operates the same MD-degree-granting public medical school model within the same Rutgers Biomedical and Health Sciences system, making it the most direct peer and ultimate consolidation partner.
• Lewis Katz School of Medicine at Temple University: Public urban medical school serving a comparable inner-city patient population with strong research funding and a Level 1 trauma center. Operates with similar mission-driven focus on community health in a major metropolitan area.
• Albert Einstein College of Medicine: Private MD-granting medical school in New York City with strong NIH-funded research enterprise and urban academic medical center model. Comparable in combining research-intensive biomedical science programs with clinical care delivery and graduate medical education in a dense Northeast market.
• New York Medical College: Private health sciences university in the NY metro area offering MD programs with significant biomedical research infrastructure and affiliated teaching hospitals. Comparable as a regional medical school combining medical education, GME, and clinical research.
• Sidney Kimmel Medical College at Thomas Jefferson University: Philadelphia-based MD-granting medical school with similar mid-Atlantic urban academic medical center profile, NIH-funded research enterprise, and affiliation with a regional hospital system. Directly comparable in mission and operational structure.
• Renaissance School of Medicine at Stony Brook University: Public MD-granting medical school within the SUNY system, similarly operating a state-affiliated academic medical center with substantial NIH research funding. Comparable in mission, public-university governance, and operating model to NJMS.

Broad incumbents

• Icahn School of Medicine at Mount Sinai: Top-tier NYC medical school with substantially larger NIH funding base and broader specialty research portfolio. Comparable in infectious disease research strength and urban academic medical center model, but operates at significantly greater scale and national ranking.

Emerging players

• University Hospital (Newark): The 519-bed Level 1 Trauma Center that serves as NJMS's primary teaching hospital. Operationally intertwined with NJMS — overlapping leadership, clinical faculty, and patient populations — making it a critical operational partner/peer rather than a separate competitor.
• Rutgers School of Public Health: Sister Rutgers school offering MPH and DrPH programs with overlapping infectious disease and global health research expertise. Part of the same Rutgers Biomedical and Health Sciences system and a likely collaborator on PHRI's TB and emerging pathogens research portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Rutgers_NJMS
• Facebookfacebook.com/RutgersIT
• Instagraminstagram.com/rutgers_njms/?hl=en

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rutgers New Jersey Medical School